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Abstract
Objectives To compare the efficacy and safety of inflix-
imab-biosimilar with other biological drugs for the treat-
ment of active ankylosing spondylitis (AS).
Methods Systematic literature review for randomized
controlled trials (RCTs) with adalimumab, etanercept, go-
limumab, infliximab and infliximab-biosimilar in AS was
performed and indirect meta-analysis (Bayesian mixed
treatment comparison) was carried out. The proportion of
patients reaching 20 % improvement by the assessment of
Spondyloarthritis International Society response criteria
(ASAS20) at weeks 12 and 24 was used as efficacy end-
points, and the occurrence of serious adverse events at week
24 was applied to compare the safety of the biologicals.
Results Altogether, 13 RCTs, identified by the systematic
literature search, were included in the analysis. Results on
the ASAS20 efficacy endpoint were reported for week 12
in 12 RCTs involving 2,395 patients, and for week 24 in 5
RCTs comprising 1,337 patients. All the five biological
agents proved to be significantly superior to placebo. Inf-
liximab showed the highest odds ratio (OR) of 7.2 (95 %
CI 3.68–13.19) compared to placebo, followed by inflix-
imab-biosimilar with OR 6.25 (95 % CI 2.55–13.14), both
assessed at week 24. No significant difference was found
between infliximab-biosimilar and other biological treat-
ments regarding their efficacy and safety.
Conclusions This is the first study which includes a
biosimilar drug in the meta-analysis of biological treat-
ments in AS. The results have proven the similar efficacy
and safety profile of infliximab-biosimilar treatment com-
pared to other biologicals.
Keywords Ankylosing spondylitis  Biological drug 
Biosimilar pharmaceuticals  Meta-analysis  Efficacy 
Safety
JEL Classification I10  I19
Introduction
So far adalimumab, etanercept, golimumab and infliximab
have been approved by the European Medicine Agency
(EMA) for the treatment of adults with severe, active
ankylosing spondylitis (AS) who have responded inade-
quately to conventional therapy (see detailed description of
the disease in Pe´ntek et al. [1] in this Supplement).
In September 2013, the first biosimilar therapy, namely
infliximab-biosimilar (CT-P13, trade names: Remsima and
Inflectra) was licensed in the EU for the treatment of AS. The
results of a Phase 1, multicenter, double-blind randomized
controlled trial (RCT) with infliximab-biosimilar (called the
PLANETAS study) were published in May, 2013 [2]. The
trial was designed to demonstrate pharmacokinetic
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equivalence and efficacy and safety comparability of inf-
liximab-biosimilar (CT-P13) and the originator infliximab in
active AS patients. The RCT was conducted at 46 sites across
10 countries in Europe, Asia and Latin America between
November, 2010 and December, 2011. Altogether, 250
patients were enrolled in the study. Besides pharmacoki-
netics, the proportions of patients achieving 20 and 40 %
improvement according to the assessment of Spondyloar-
thritis International Society1 response criteria (ASAS20 and
ASAS40) at weeks 14 and 30 were the endpoints to assess
efficacy [3]. (See the definition of ASAS response criteria in
the Methods Section). No significant differences were found
in the efficacy and safety of the originator infliximab and
infliximab-biosimilar. According to the study results,
ASAS20 and ASAS40 responses at week 30 were 70.5 and
51.8 % for infliximab-biosimilar and 72.4 and 47.4 % for
originator infliximab, respectively. The authors concluded
that pharmacokinetic, efficacy and safety profiles of the
infliximab-biosimilar and the originator infliximab were
equivalent in patients with active AS [2].
According to our knowledge, no meta-analyses have
been published yet in AS, which compare the efficacy and
safety of the infliximab-biosimilar treatment to the other
biological drugs indicated in AS. Thus, the aim of this
study was to carry out a systematic literature review and
meta-analysis of published RCTs in order to compare the
efficacy and safety of infliximab-biosimilar to adalimumab,
etanercept, golimumab and infliximab in AS.2
Besides the PLANETAS trial, no other RCTs, present-
ing head-to-head comparison of biologicals, have been
published yet in this diagnosis [4]. Due to the difference in
comparators across the trials (infliximab-biosimilar is
compared to infliximab in the PLANETAS study, while
other biologicals are compared to placebo), traditional
methods cannot be applied for the comparison. Therefore,
we used an indirect comparison method, namely mixed
treatment comparison (MTC) to evaluate the efficacy and
safety of biological treatments. MTC permits indirect
comparisons between study drugs with different compara-
tors as well [5, 6].
Methods
Treatments
In the current analysis adalimumab, etanercept, golimumab
and infliximab are considered as comparators of
infliximab-biosimilar as these biologicals are recom-
mended by the EMA for the treatment of AS. Only doses
recommended by the EMA were considered in the analysis:
adalimumab (40 mg every other week as a subcutaneous
injection); etanercept (25 mg twice weekly, or 50 mg once
weekly as a subcutaneous injection); golimumab (50 mg
once a month as a subcutaneous injection); infliximab
(5 mg/kg at 0, 2, 6 weeks and then every 6–8 weeks as
intravenous infusions over a 2-h period) and infliximab-
biosimilar (CT-P13) (5 mg/kg at 0, 2, 6 weeks and then
every 6–8 weeks as intravenous infusions over a 2-h
period).
Literature search
Electronic databases (Medline and Cochrane Library) as
well as references of retrieved articles were searched. The
Cochrane highly sensitive search strategy [7] was applied
to identify randomized controlled publications and was
combined with the disease (ankylosing spondylitis, anky-
losing spondyloarthritis, spondyloarthritide) and drug
names for adalimumab, etanercept, golimumab and inflix-
imab.3 We carried out the search for the period between
November 1, 2005 and August 20, 2013. To identify RCTs
from earlier years, we relied on the systematic review of
McLeod et al. [8] published in 2007, which assessed the
comparative clinical effectiveness of adalimumab, etaner-
cept and infliximab for the treatment of AS. A separate
search was carried out to identify RCTs with the biosimilar
agent, using its generic name (CT-P13) as search term, and
in this case no further restrictions were applied.
Exclusion and inclusion criteria
Double-blind RCTs in AS with parallel design, with full
paper obtainable were included. Non randomized or
uncontrolled studies, observational studies, case series,
letters to editor, studies with no abstracts or with conference
abstracts only were not included. A further inclusion cri-
terion was that AS patients, diagnosed based on the modi-
fied New York criteria [9], in at least one arm of the trial
must receive adalimumab, etanercept, golimumab, inflix-
imab or infliximab-biosimilar treatment at the labelled dose.
Studies which examined only off-label doses, or other than
the suggested administration (e.g. infliximab combined with
1 Former Asessment in Ankylosing Spondylitis.
2 The search dates were November 1, 2009 to August 20, 2013.
Certolizumab pegol was registered for the treatment of AS on 19
September 2013, thus it was not included in our analysis.
3 (‘‘Ankylosing spondylitis’’ OR ‘‘ankylosing spondyloarthritis’’ OR
‘‘spondyloarthritide’’) AND (‘‘adalimumab’’ OR ‘‘infliximab‘‘ OR
‘‘golimumab’’ OR ‘‘etanercept‘‘) AND [(randomized controlled
trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR
placebo[tiab] OR ‘‘clinical trials as topic’’[MeSH Terms] OR
randomly[tiab] OR trial[ti]) NOT (‘‘animals’’[MeSH Terms] NOT
‘‘humans’’[MeSH Terms])] AND (‘‘2005/11/01’’[PDAT]: ‘‘2013/08/
20’’[PDAT]).
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methotrexate) studies reporting solely on laboratory mea-
sures aimed at investigating disease, or treatment mecha-
nisms and which do not report relevant clinical outcomes
were excluded. Studies involving patients younger than
18 years were also excluded, as well as pilot studies.
Data extraction
We used the same data extraction process and quality
assessment of the RCTs as in our previous study in which we
assessed the efficacy and safety of infliximab-biosimilar in
another inflammatory rheumatic disease, rheumatoid
arthritis (RA). Details have been published elsewhere [10].
In brief, data on study design, patients’ demographic and
morbidity characteristics, treatment interventions, endpoints
and duration of follow-up were subtracted. The quality of
selected studies was evaluated using the JADAD-score [11].
Endpoints
The proportions of patients with ASAS20 response at
weeks 12 and 24 were used as efficacy endpoints in the
meta-analysis of AS trials. The ASAS20 improvement
criteria requires improvement of C20 % and C1 unit in at
least 3 of 4 well-defined specific domains (patient global
assessment, pain, function and inflammation) on a scale of
10 and no worsening of C20 % and C1 in remaining
domain on a scale of 10 [3]. To evaluate the safety of
biological therapies, the occurrence of serious adverse
events at week 24 was used as a safety endpoint in the
analysis. We could not carry out the safety analysis at week
12, as the infliximab-biosimilar study presented safety
results only at week 30 [2].
Meta-analysis
Mixed treatment comparison (MTC) was applied in the
analysis [5, 6]. We estimated the posterior densities for all
unknown parameters using MCMC (Markov chain Monte
Carlo) for each model in WinBUGS version 1.4.3 (MRC
Biostatistics Unit, Cambridge, UK). We applied a random
effects model to estimate the odds ratios (OR) as the
measure of relative treatment effect. We also present the
95 % credibility intervals (CI) which contain the true value
of OR with 95 % probability.
Results
Literature review
Our literature search for the period between November 1,
2005 and August 20, 2013 yielded 336 potential citations
for RCTs. Among them seven RCTs in AS with the target
drugs of our study were identified. Five of them met our
inclusion criteria [12–16]. One study was not enrolled as it
examined off-label infliximab therapy (3 mg/kg) [17]. To
have comparable results, one study was excluded as inf-
liximab was given in combination with methotrexate [18].
Till November 2005, nine RCTs identified by the system-
atic review of McLeod et al. [8] were screened for eligi-
bility. Seven of them met our enrollment criteria, and were
included in the current meta-analysis [19–25]. (One study
[26] was excluded as it examined the effect of etanercept at
week 6, and another study was published later in a scien-
tific journal by van der Heijde et al. [13], which was
identified by our search as well in the Medline database).
The search for infliximab-biosimilar did not identify any
other RCT than the PLANETAS trial [2].
Thus, altogether 13 studies were included in the meta-
analysis. Eight of them were 12-week trials: one with
infliximab [24], five with etanercept [13–15, 21, 22] and
two with adalimumab [12, 20]. Five of 13 studies were at
least 24-week trials: one with infliximab [25], one with
adalimumab [19], one with etanercept [23], one with go-
limumab [16] and one with infliximab-biosimilar [2].
The main characteristics of the RCTs, i.e. the number of
patients enrolled, the treatment arms and the JADAD-
scores are presented in Table 1.
Mixed treatment comparison meta-analysis: efficacy
and safety
Efficacy
The infliximab-biosimilar study and Inman et al. [16] go-
limumab study presented ASAS20 results at week 14, and
the Gorman et al. [21] etanercept study at week 16
(4 months). These studies were pooled with trials present-
ing results for week 12. In this way, results of twelve studies
involving 2,395 patients were analyzed for ASAS20 end-
point at week 12. All biologicals were found to be signifi-
cantly superior to placebo. Compared to placebo, infliximab
showed the highest OR for ASAS20 response at week 12,
OR 6.74 (3.81–11.3), followed by infliximab-biosimilar OR
6.39 (2.75–12.78) and golimumab OR 5.7 (2.88–10.44).
Results are presented in Table 2.
Four studies reported ASAS20 response at week 24. The
infliximab-biosimilar RCT presented ASAS20 results at week
30. However, patients in this trial received the same number of
infusions as patients in the 24-week infliximab study. There-
fore, we pooled these five studies involving 1,337 patients in
the analysis of ASAS20 response at week 24.
At week 24, infliximab showed the highest ORs com-
pared to placebo [OR 7.2 (95 % CI 3.68–13.19)], followed
by infliximab-biosimilar [OR 6.25 [95 % CI 2.55–13.14)]
Comparative efficacy and safety of biosimilar infliximab
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and adalimumab [OR 4.81 (95 % CI 2.67–8.18)], see
Table 2. All biologicals were found to be significantly
superior to placebo.
The results of the pairwise comparison did not show
significant differences between the efficacy of infliximab-
biosimilar and the other biologicals in terms of ASAS20
response: neither at week 12, nor at week 24 (see Fig. 1).
Safety
The occurrence of severe adverse events (AE) was exam-
ined at week 24. Five AS studies involving 1,337 patients
reported the occurrence of severe AEs at week 24. At this
endpoint the lower ORs are in favor of biologicals, as the
lower the OR, the lower the chance of the occurrence of
serious AEs compared to placebo.
Golimumab gave the lowest ORs compared to placebo
[OR 0.69 (95 % CI 0.14–2.1)], followed by adalimumab
[OR 1.57 (95 % CI 0.27–5.72)] and infliximab-biosimilar
[OR 2.31 (95 % CI 0.17–11.43)]. We have not found sig-
nificant difference between placebo and biological treat-
ments regarding safety.
Regarding the pairwise comparison of the treatments,
we found no significant difference in the safety of inflix-
imab-biosimilar and other biological treatments (see
Fig. 2).
Table 2 The efficacy of
infliximab-biosimilar and other
biologicals compared to placebo
in AS, results of the mixed
treatment comparison
a Results for weeks 14 and 30
were available and considered
for infliximab-biosimilar
Substance ASAS20 at week 12,
OR (95 % CI)
ASAS20 at week 24,
OR (95 % CI)
Serious adverse events
OR (95 % CI)
Adalimumab 4.65 (3.29–6.43) 4.81 (2.67–8.18) 1.57 (0.27–5.72)
Etanercept 4.35 (3.09–5.96) 4.76 (2.73–7.81) 2.36 (0.64–6.58)
Golimumab 5.7 (2.88–10.44) 4.53 (2.32–8.22) 0.69 (0.14–2.1)
Infliximab 6.74 (3.81–11.3) 7.2 (3.68–13.19) 2.71 (0.35–12.03)
Infliximab-biosimilara 6.39 (2.75–12.78) 6.25 (2.55–13.14) 2.31 (0.17–11.43)
Fig. 1 Efficacy of infliximab-biosimilar compared to other biolog-
icals in AS, results of mixed treatment comparison (ASAS20 response
at weeks 12 and 24). Results for weeks 14 and 30 were available and
considered for infliximab-biosimilar. Note: the Figure presents odds
ratios (OR) between treatments. If the point estimate is greater than 1,
then the biosimilar treatment is more effective (although not
necessarily statistically significantly more effective) compared to
the originator biologicals. Credibility intervals provide information on
whether the difference between treatments is statistically significant.
If the CI contains the value 1, the difference is not statistically
significant
Comparative efficacy and safety of biosimilar infliximab
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Discussion
Our study, based on the meta-analysis of available RCTs,
involving 2,395 AS patients at week 12 and 1,337 AS patients
at week 24, has demonstrated that there is no significant dif-
ference in the efficacy of infliximab-biosimilar and other
biological drugs in terms of ASAS20 improvement. The
results showed no significant differences in the safety of inf-
liximab-biosimilar and biologicals either.
Some of the former meta-analyses synthetized the evidence
of a single biological agent against placebo [27–29]. All these
studies concluded that biological agents were superior to
placebo. Thaler et al. [30] in their extensive review (2012)
compared the efficacy and safety of 12 biologicals in seven
inflammatory diseases, including AS, based on literature
published between January 2009 and October 2011. However,
they have not presented results regarding the indirect com-
parison of available treatments in AS.
McLeod et al. [8] assessed the comparative clinical
effectiveness and cost-effectiveness of adalimumab, eta-
nercept and infliximab for the treatment of AS. The authors
carried out traditional direct and indirect comparisons of
the treatments. Nine placebo-controlled RCTs were inclu-
ded in their meta-analysis. According to their findings the
difference between biologicals was not significant.
Mixed treatment comparison (MTC) was used by Mi-
gliore et al. [4] and Shu et al. [31].
Shu et al. compared the effectiveness of different doses
of adalimumab, golimumab and infliximab in terms of
ASAS20 response at week 12. Fourteen RCTs were
included in their analysis.4 All drug dosages applied in the
RCTs were assessed, while we focused only on treatment
arms with the doses recommended by the EMA.
Nevertheless, authors came to the same conclusion as us,
namely that infliximab 5 mg/kg at 0, 2, 6 weeks was the
best efficacious therapy [OR 6.53 (95 % CI 3.35, 11.61)]
compared to placebo [31]. No significant differences were
found between the biological treatments either.
Migliore et al. [4] compared ASAS20 response at week
24 between biological agents. Three RCTs were included
in their analysis, as the 24-week golimumab RCT and the
recently published RCT with infliximab-biosimilar were
not included [4]. The authors found no significant differ-
ences when comparing directly one biological agent
against another. When compared with placebo, infliximab
increased the probability of response by 7 times (OR 6.8),
adalimumab by 4 times (OR 4.4), and etanercept by 5 times
(OR 4.9). These results are in line with our findings, and
confirm the validity of our study.
We have to acknowledge some limitations of our study.
First, a potential weakness of this meta-analysis arises from
the fact that the trials from which data are combined are
likely to differ in their design. For example, the infliximab-
biosimilar study reports efficacy and safety results at week
14 and 30 while most of the others do so for week 12 and
24; that is infliximab-biosimilar results are from 2 to 6
weeks later, respectively. However, we do not expect
strong bias related to this difference as patients in the
infliximab-biosimilar study received the same number of
infusions as patients in the infliximab study. Also, patient
characteristics (age, disease duration, baseline BASDAI
score) varied slightly across studies. Furthermore, only the
primary efficacy outcome was assessed in this analysis
(ASAS20). Other efficacy endpoints were not investigated
as, on the one hand, some of the RCTs have not reported
ASAS40, and on the other hand, the infliximab-biosimilar
RCT did not assess another activity score, the 50 %
improvement of the initial disease activity score of the
Bath ankylosing spondylitis disease activity index (BAS-
DAI50). Also, the safety analysis was carried out only for
Fig. 2 The safety of infliximab-biosimilar compared to other biologicals
in AS: serious adverse events (AE). Results for week 30 were available and
considered for infliximab-biosimilar. Note: the Figure presents odds ratios
(OR) between treatments. If the point estimate is lower than 1 then the
biosimilar treatment is safer (although not necessarily statistically
significantly safer). Credibility intervals provide information on whether
the difference between treatments is statistically significant. If the CI
contains the value 1, the difference is not statistically significant
4 Shu et al.’s study included two additional RCTs, which were not
included in our analysis—for further explanation, see the Results
Section.
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the occurrence of serious adverse events at week 24, since
the infliximab-biosimilar study presented safety results
only at week 30. In this way only five RCTs were included
in the safety analysis. Despite these limitations, we believe
that our analysis contributes with important results to the
evidence-based health care evaluation of AS that might
support clinical as well as financial decision making.
In conclusion, infliximab-biosimilar has recently been
approved by the European Medicines Agency for the
treatment of adults with active AS and this first meta-
analysis suggests that it is similar in both efficacy and
safety to other biologicals. Further head-to-head compari-
sons, continuous data collection and benefit-risk assess-
ment might confirm our results.
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